Enliven Therapeutics (ELVN)
ELVN · BiotechSign PipelinePipeline Overview
- Therapeutic Focus
- Precision Oncologysrc
Signal Snapshot
4
Clinical Trials (ClinicalTrials.gov aggregate)
0
Catalyst Records
5
Publications on Record
4 Phase 1
Trial Phase Mix
ClinicalTrials.gov aggregate as of 2026-09-29. Source
Recent Publications
- Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma. — J Immunother Cancer (2026) PMID 42767768
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. — J Immunother Cancer (2026) PMID 42705861
5 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Enliven Therapeutics.
Full ELVN Data Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.